NovelMed Therapeutics Press Releases

• Published on June 17, 2024 - 12:30 GMT

  FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis-a Chronic Rare Disease in Nephrology

  -- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients CLEVELAND, OHIO, UNITED STATES, June 17, 2024 /⁨EINPresswire.com⁩/ -- NovelMed proudly announces the U.S. Food …

  Distribution channels: Business & Economy, Companies ...
• Published on April 15, 2024 - 12:30 GMT

  The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria

  CLEVELAND, OHIO, UNITED STATES, April 15, 2024 /⁨EINPresswire.com⁩/ -- NovelMed today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NM5072, an AP blocker anti-Properdin antibody, for the treatment of …

  Distribution channels: Business & Economy, Companies ...
• Published on February 12, 2024 - 13:30 GMT

  Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment!

  CLEVELAND, OHIO, UNITED STATES, February 12, 2024 /⁨EINPresswire.com⁩/ -- NovelMed today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody …

  Distribution channels: Business & Economy, Companies ...
• Published on January 8, 2024 - 13:30 GMT

  USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

  CLEVELAND, OH, UNITED STATES, January 8, 2024 /⁨EINPresswire.com⁩/ -- NovelMed, a clinical-stage biopharmaceutical company with expertise in inflammatory and complement-related diseases, is pleased to announce that the United States Adopted Name (USAN) …

  Distribution channels: Business & Economy, Companies ...